Cytomegalovirus (CMV) infection is one of the most common complications affecting solid organ transplant recipients.

Hundreds of participants gathered at Sawyer Point and Yeatman's Cove for the Crohn's and Colitis Foundation's largest fundraising event.

Obefazimod shows efficacy and favourable safety in patients with moderate to severely active ulcerative colitis in a 96-week maintenance study.

TREMFYA® (guselkumab) positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks ...

That’s the aspirational way to use AI in the treatment of ulcerative colitis, but there are also novel ways that I think are maybe even much closer, which are things like AI in endoscopy, and ...

Wall Street was weighing the gravity of the death from acute liver failure of a patient who was treated for Duchenne muscular dystrophy (DMD) with Sarepta Therapeutics Inc.’s gene therapy, Elevidys ...

In patients with ulcerative colitis, vedolizumab outperformed infliximab as a second-line therapy following failure of anti-TNF therapy.

OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO Lusvertikimab achieved statistical significance on ...

Researchers say they found that infection with a common virus that can be transmitted from mother to fetus before birth significantly worsens an often-fatal complication of premature birth called ...

ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease New detailed data from the RELIEVE UCCD study support overall efficacy and safety of ...

Iterative Health will present five abstracts at the European Crohn’s & Colitis Organization (ECCO) meeting in Berlin, Germany, Feb. 19-22, 2025.

Mirikizumab treatment is safe and efficacious for ulcerative colitis up to 152 weeks in those with and without previous biologic therapy failure.